

Select Publications

1. Lucas MW, **Kelly CM**. Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights. *Cancer Management and Research*. 2022;14:2493-2506
2. Galactionova K, Loibl S, Salari P, Marmé F, Martin M, Untch M, Bonnefoi HR, Kim S-B, Bear HD, McCarthy N, Gelmon KA, García-Sáenz JA, **Kelly CM**, et al. (2022) Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial. *Front. Oncol.* 12:886831. doi: 10.3389/fonc.2022.886831
3. Silva R, Moran B, Das S, Mulligan, N, Doughty, M, Treacy, A, Sheahan, K, **Kelly CM** et al. Investigating a clinically actionable BRAF mutation for monitoring low-grade serous ovarian cancer: A case report. *Case Rep Womens Health*. 2022;34:e00395
4. Nolan K, O'Donnell K, Moloney FJ, **Kelly CM**, Potter S. The impact of a See and Treat Clinic on skin cancer treatment time. *Journal of Plastic, Reconstructive & Aesthetic Surgery*. 2022;75(2):893-939
5. Donohoe F, O'Meara Y, Roberts A, et al. Using menopausal hormone therapy after a cancer diagnosis in Ireland. *Irish Journal of Medical Science (1971 -)*. 2022
6. Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, Bianchini G, Russo S, Ciruelos EM, Greil R, Semiglazov V, Colleoni M, **Kelly C**, Mariani G, Del Mastro L, Maffei I, Valagussa P, Viale G: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study. *Annals of Oncology* 2022.
7. Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, **Kelly CM**, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN: 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. *N Engl J Med* 2021, 385:2336-47
8. Chew S, Carroll HK, Darwish W, Boychak O, Higgins M, McCaffrey J, **Kelly CM**: Characterization of Treatments and Disease Course for Women with Breast Cancer Brain Metastases: 5-Year Retrospective Single Institution Experience. *Cancer management and research* 2021, 13:8191-8
9. Chew, S. M., M. Lucas, M. Brady and **C. M. Kelly** (2021). "SKAP2-BRAF fusion and response to an MEK inhibitor in a patient with metastatic melanoma resistant to immunotherapy." *BMJ Case Reports* 14(6): e238494.
10. Prior, L., H. Featherstone, D. O'Reilly, K. Nugent, M. Lim, J. McCaffrey, M. J. Higgins and **C.M. Kelly**. Competing mortality risks: predicted cardiovascular disease risk versus predicted risk of breast cancer mortality in patients receiving adjuvant chemotherapy in a single Irish center. *Cardiooncology*. 2021;7(1):8
11. O'Reilly D, Sendi MA, **Kelly CM**. Overview of recent advances in metastatic triple negative breast cancer. *World J Clin Oncol*. 2021;12(3):164-82
12. AlSendi M, O'Reilly D, Zeidan YH, **Kelly CM**. Oligometastatic Breast Cancer: Are We There Yet? *Int J Cancer*. 2021
13. Bayani, J., C. Poncet, C. Crozier, A. Neven, T. Piper, C. Cunningham, M. Sobol, S. Aebi, K. Benstead, O. Bogler, L. Dal Lago, J. Fraser, F. Hilbers, I. Hedenfalk, L. Korde, B. Linderholm, J. Martens, L. Middleton, M. Murray, **C. Kelly**, C. Nilsson, M. Nowaczyk, S. Peeters, A. Peric, P. Porter, C. Schröder, I. T. Rubio, K. J. Ruddy, C. van Asperen, D. Van Den Weyngaert, C. van Deurzen, E. van Leeuwen-Stok, J.

- Vermeij, E. Winer, S. H. Giordano, F. Cardoso and J. M. S. Bartlett (2021). "Evaluation of multiple transcriptomic gene risk signatures in male breast cancer." *npj Breast Cancer* 7(1): 98
14. Lynch, S. M., N. M. Russell, S. Barron, C.-J. A. Wang, T. Loughman, P. Dynoodt, B. Fender, C. Lopez-Ruiz, A. O'Grady, K. M. Sheehan, J. Fay, V. Amberger-Murphy, A. Saha, R. Klinger, C. A. Gonzalez, N. Al-Attar, A. Rahman, D. O'Leary, F. T. Lanigan, A. P. Bracken, J. Crown, **C. M. Kelly**, D. P. O'Connor and W. M. Gallagher. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors. *European Journal of Cancer*. 2021;152:78-89
 15. McSorley, L. M., M. Tharmabala, F. Al Rahbi, K. McSorley, S. Chew, D. Evoy, J. G. Geraghty, R. S. Prichard, J. Rothwell, D. P. McCartan, E. W. McDermott, M. Keane, M. J. Kennedy, S. O'Reilly, S. J. Millen, J. P. Crown, L. M. Smyth, **C. M. Kelly**, C. M. Quinn and J. M. Walshe (2021). "Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland." *Breast Cancer Res Treat* 188(3): 789-798.
 16. O'Reilly, D., H. Carroll, M. Lucas, J. Sui, M. Al Sendi, D. McMahon, W. Darwish, R. McLaughlin, M. R. Khan, H. O. Sullivan, S. Chew, C. Dennehy, **C. M. Kelly**, J. McCaffrey, M. Greally, D. Carney and M. J. Higgins. Virtual oncology clinics during the COVID-19 pandemic. *Ir J Med Sci*. 2021
 17. Mallett V, Linehan A, Burke O, Healy L, Picardo S, **Kelly CM**, et al. A Multicenter Retrospective Review of Systemic Anti-Cancer Treatment and Palliative Care Provided to Solid Tumor Oncology Patients in the 12 Weeks Preceding Death in Ireland. *Am J Hosp Palliat Care*. 2021:1049909120985234
 18. Loibl, S., F. Marme, M. Martin, M. Untch, H. Bonnefoi, S. B. Kim, H. Bear, N. McCarthy, M. Mele Olive, K. Gelmon, J. Garcia-Saenz, **C. M. Kelly**, T. Reimer, M. Toi, H. S. Rugo, C. Denkert, M. Gnant, A. Makris, M. Koehler, C. Huang-Bartelett, M. J. Lechuga Frean, M. Colleoni, G. Werutsky, S. Seiler, N. Burchardi, V. Nekljudova and G. von Minckwitz. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. *J Clin Oncol*. 2021:JCO2003639
 19. Keegan, N. M., S. J. Furney, J. M. Walshe, G. Gullo, M. J. Kennedy, D. Smith, J. McCaffrey, **C. M. Kelly**, K. Egan, J. Kerr, M. Given, P. O'Donovan, A. Hernando, A. Teiserskiene, I. Parker, E. Kay, A. Farrelly, A. Carr, G. Calzaferri, R. McDermott, M. M. Keane, L. Grogan, O. Breathnach, P. G. Morris, S. Toomey and B. T. Hennessy. Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PanTHER". *Cancers (Basel)*. 2021;13(6)
 20. Culbertson MG, Bennett K, **Kelly CM**, Sharp L, Cahir C. The psychosocial determinants of quality of life in breast cancer survivors: a scoping review. *BMC Cancer*. 2020;20(1):948
 21. Giblin, G. T., C. Dennehy, H. Featherstone, R. Clarke, L. Murphy, D. Timlin, C. O'Keane, N. Mulligan, **C. M. Kelly** and E. Joyce. Subclinical Myocarditis After Combination Immune Checkpoint Inhibitor Therapy. *Circ Heart Fail*. 2021;14(2):e007524
 22. Krop, I., V. Abramson, M. Colleoni, T. Traina, F. Holmes, L. Garcia-Estevez, L. Hart, A. Awada, C. Zamagni, P. G. Morris, L. Schwartzberg, S. Chan, A. Gucalp, L. Biganzoli, J. Steinberg, L. Sica, M. Trudeau, D. Markova, J. Tarazi, Z. Zhu, T.

- O'Brien, **C. M. Kelly**, E. Winer and D. A. Yardley (2020). "A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer." *Clin Cancer Res* 26(23): 6149-6157.
23. Montemurro, F., S. Delaloe, C. H. Barrios, R. Wuerstlein, A. Anton, E. Brain, T. Hatschek,
24. **C. M. Kelly**, C. Peña-Murillo, M. Yilmaz, M. Donica, and P. Ellis. "Trastuzumab Emtansine (T-Dm1) in Patients with Her2-Positive Metastatic Breast Cancer and Brain Metastases: Exploratory Final Analysis of Cohort 1 from Kamilla, a Single-Arm Phase I/II Clinical Trial." *Annals of Oncology* (2020/07/05/ 2020). <http://dx.doi.org/https://doi.org/10.1016/j.annonc.2020.06.020>.
25. Kearns, C, Feighery R, Mc Caffrey J, Higgins M, Smith M, Murphy V, **Kelly CM**. "Understanding and Attitudes toward Cancer Clinical Trials among Patients with a Cancer Diagnosis: National Study through Cancer Trials Ireland." *Cancers* 12, no. 7 (2020): 1921. <https://www.mdpi.com/2072-6694/12/7/1921>.
26. Greally, M., Kieley, J., Watson, G. A., Das, G., Malouf, C., McSorley, L., Coleman, N., Quinn, C., McDermott, E. W., Gullo, G., Crown, J., Prichard, R. S., **Kelly, C. M.** and Walshe, J. M. (2019). Where youth matters-clinicopathologic characteristics and emerging trends in treatment and outcomes in young Irish women with breast cancer. *Ir J Med Sci*, 188(1), 59-67. doi:10.1007/s11845-018-1832-z
27. Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O'Shaughnessy, J.,
28. Gradishar, W., Schmid, P., Winer, E., **Kelly, C.**, Nanda, R., Gucalp, A., Awada, A., Garcia-Estevez, L., Trudeau, M. E., Steinberg, J., Uppal, H., Tudor, I. C., Peterson, A. and Cortes, J. (2018). Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. *J Clin Oncol*, 36(9), 884-890. doi:10.1200/JCO.2016.71.3495
29. Cardoso, F., Bartlett, J. M. S., Slaets, L., van Deurzen, C. H. M., van Leeuwen-Stok, E., Porter, P., Linderholm, B., Hedenfalk, I., Schroder, C., Martens, J., Bayani, J., van Asperen, C., Murray, M., Hudis, C., Middleton, L., Vermeij, J., Punie, K., Fraser, J., Nowaczyk, M., Rubio, I. T., Aebi, S., **Kelly, C.**, Ruddy, K. J., Winer, E., Nilsson, C., Dal Lago, L., Korde, L., Benstead, K., Bogler, O., Goulioti, T., Peric, A., Litiere, S., Aalders, K. C., Poncet, C., Tryfonidis, K. and Giordano, S. H. (2018). Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. *Ann Oncol*, 29(2), 405-417. doi:10.1093/annonc/mdx651